Technologies
PDF


WARF: P06406US

Stable Collagen Mimics


INVENTORS -

Ronald Raines, Matthew Shoulders, Jonathan Hodges

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing several new collagen mimics that use steric, rather than stereoelectronic, effects to achieve increased stability.
OVERVIEWCollagen, the most abundant protein in vertebrates, provides structure for tissues and plays a key role in wound healing. In connective tissue, individual collagen molecules are wound together in tight triple helices that are further organized into strong fibrils. The collagen polypeptide chains are composed of approximately 300 repeats of the sequence Xaa-Yaa-Gly, where Xaa is often proline (Pro), Yaa is often hydroxyproline (Hyp) and the third residue is always glycine (Gly). Stereoelectronic effects cause the rings in the Xaa and Yaa positions to have complementary puckers, enhancing the stability of collagen.
THE INVENTIONUW-Madison researchers have developed several new collagen mimics that use steric, rather than stereoelectronic, effects to achieve increased stability. The collagen mimics consist of a tripeptide unit with the formula (Xaa-Yaa-Gly)n, where either Xaa or Yaa is a bulky, non-electron withdrawing, 4-substituted proline derivative that contains an alkyl or thiol group, and n is a positive integer of at least 3.

Replacing a proline derivative at the Xaa or Yaa position results in steric effects that increase the stability of the helix. Specifically, three collagen variants that are more stable than native collagen are (Pro-Mep-Gly)7, (mep-Pro-Gly)7 and (mep-Mep-Gly)7, where Mep is (2S,4S)-4-methylproline and mep is (2S,4R)-4-methylproline. In addition, a fluoroproline may be substituted at the Xaa or Yaa position to further increase the strength and stability of the collagen.
APPLICATIONS
  • Treatment of diseases associated with abnormal collagen, including arthritis, osteoporosis and osteogenesis imperfecta
  • Wound healing
  • Artificial skin
  • Tissue welding
  • A substitute for collagen in other applications requiring high strength
KEY BENEFITS
  • Forms a stronger and more stable triple helix than native collagen
  • The methyl group can be modified with almost any functional group, enabling the design of a hyperstable triple helix that displays useful functional groups for applications in biomaterials science and nanotechnology.
ADDITIONAL INFORMATION
For More Information About the Inventors
Related Technologies
Contact Information
For current licensing status, please contact Joshua Carson at jcarson@warf.org or (608) 890-1622.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.